ID   NS-Meg
AC   CVCL_S966
SY   NS-MEG
DR   Cosmic; 1012108
DR   Wikidata; Q54931045
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7719248;
RX   PubMed=10071072;
RX   PubMed=10576511;
RX   PubMed=16408098;
CC   Population: Japanese.
CC   Doubling time: 72 hours (PubMed=7719248).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (PubMed=7719248; PubMed=10071072; PubMed=10576511).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 19-12-24; Version: 13
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=7719248; DOI=10.1002/stem.5530130108;
RA   Tsuyuoka R., Takahashi T., Suzuki A., Sasaki Y., Nakamura K.,
RA   Fukumoto M., Ohmori K., Ohno Y., Nakao K.;
RT   "A newly established megakaryoblastic/erythroid cell line that
RT   differentiates to red cells in the presence of erythropoietin and
RT   produces platelet-like particles.";
RL   Stem Cells 13:54-64(1995).
//
RX   PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=10576511; DOI=10.1016/S0145-2126(99)00131-9;
RA   Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.;
RT   "ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.";
RL   Leuk. Res. 23:1055-1060(1999).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//